Middle East And Africa Lipid Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 496.85 Million |
 Market Size (Forecast Year) |
USD 878.32 Million |
 CAGR |
% |
| Major Markets Players |
>中东和非洲脂质市场，按类型（天然脂质和合成脂质）、脂质系统（中性脂质、细菌脂质、荧光脂质、生物活性脂质、可聚合脂质、头部改性脂质等）、输送系统（脂质体、固体脂质纳米颗粒、纳米结构脂质载体、类脂质体、转移体等）、来源（蛋黄、大豆、非转基因大豆、纯化油、纯化脂肪酸等）、最终用户（制药业、生物技术业、学术和研究机构、化妆品业等）、分销渠道（直接招标、零售销售等）划分 - 行业趋势和预测到 2030 年。
中东和非洲脂质市场分析和见解
全球慢性病的日益流行增加了市场的需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者高度关注各种产品的发布和药物的批准。此外，食品和饮料、化妆品行业等其他行业对脂质的需求不断增加，也促进了脂质市场的需求增长。
医疗保健支出的增加、市场参与者的战略举措为市场带来了机遇。然而，脂质纳米颗粒生产的不同制造挑战以及新兴经济体缺乏医疗保健设施是市场增长的关键挑战。
预计中东和非洲脂质市场将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 7.4% 的复合年增长率增长，预计到 2030 年将从 2022 年的 4.9685 亿美元达到 8.7832 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按类型（天然脂质和合成脂质）、脂质系统（中性脂质、细菌脂质、荧光脂质、生物活性脂质、可聚合脂质、头部修饰脂质等）、递送系统（脂质体、固体脂质纳米颗粒、纳米结构脂质载体、类脂质体、转移体等）、来源（蛋黄、大豆、非转基因大豆、纯化油、纯化脂肪酸等）、最终用户（制药行业、生物技术行业、学术和研究机构、化妆品行业等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区 |
|
涵盖的市场参与者 |
Alnylam Pharmaceutical, Inc.、Croda International Plc.、Moderna Inc.、BioNTech SE.、Pfizer Inc.、Evonik Industries AG、Lipoid GmbH、Matreya LLC、VAV Life Sciences Pvt Ltd.、Curia Middle East and Africa Inc.、Cargill, Incorporated、Gattefossé、CD Bioparticles、Merck KGaA、NOF EUROPE GmbH、ABITEC、Cayman Chemical、CordenPharma International、CHEMI SpA、DSM、BASF SE、Tokyo Chemical Industry Co., Ltd.、ADMSIO、Stepan Company 和 Kerry |
市场定义
脂质可以定义为存在于动物、植物和微生物中的一组有机化合物。它们包括固醇、蜡、脂肪和脂溶性维生素。脂质具有执行各种活动的能力。同时，它们以毒性低而闻名。脂质的这些特性有助于有效的药物输送。因此，它们越来越多地用作药物生产中的赋形剂。这一因素推动了中东和非洲药用脂质市场的增长。
近来，全球医疗保健行业正在经历重大变革。药物输送技术的发展以及药物处方集的纳入正在成为药物脂质市场增长的驱动力。快速慢性健康问题的增长以及快速向患者输送药物是推动中东和非洲药物脂质市场增长的关键因素之一。
脂质市场动态
驱动程序
-
慢性病患病率上升
慢性病的负担在全球范围内迅速增加。根据世界卫生组织 (WHO) 的数据，2021 年慢性病的贡献率约为 60%，占死亡人数的 60%。在大多数西方国家，慢性病数量增加的主要原因是老龄人口的持续增加。心血管疾病、神经系统疾病和其他各种慢性疾病等慢性病数量的增加导致对各种药物的需求增加，这将推动未来几年中东和非洲脂质市场的增长。
-
食品饮料和化妆品行业对脂质的需求不断增加
医药行业对脂质的需求非常高，因为它用于开发市场上的各种药物。此外，食品饮料和化妆品等其他行业对脂质的需求也在增加。
脂质是膳食补充剂配方中必不可少的成分，因为它们含有大量能量和脂溶性维生素。由于 COVID-19 疫情，人们对健康的担忧日益增加，推动了中东和非洲对膳食补充剂的需求。此外，多种形式和口味的膳食补充剂的出现使其在所有年龄段都更容易被社会接受。预计膳食补充剂消费的增长将在预测的几年内推动对脂质的需求。
-
药物研发的兴起
在制药行业，脂质和聚合物被视为配制各种药物的支柱辅料。它们被用作稳定剂、增溶剂、渗透促进剂和转染剂。预计在预测期内，各种剂型的配方中越来越多地采用天然、合成、半合成或完全人工的脂质和聚合物将推动市场的发展。
机会
-
医疗支出增加
随着各国人民的可支配收入增加，全球医疗支出也随之增加。此外，为满足人口需求，政府机构和医疗机构正在主动加快医疗支出。医疗支出的增加同时有助于医疗机构改善其对各种疾病的治疗设施，近年来这种现象非常普遍。
-
主要参与者的战略举措
全球范围内，各类疾病的发病率和严重程度都在上升。研究质量的大幅提高和研究机会的增加得益于市场参与者采取的各种战略举措。多年来，他们采取了产品发布、合作、合并、收购等举措，预计将引领和创造更多市场机会。赢创投资于其位于德国哈瑙和多森海姆工厂的特种脂质生产的短期增长，这些工厂为辉瑞/BioNTech 疫苗提供了四种脂质中的两种。据 Spencer 称，第一批产品已于 2021 年 4 月交付给 BioNTech，比原计划提前了几个月。
限制/挑战
脂质合成成本高，原料成本增加
脂质药物的开发过程需要巨额成本。因为需要确定概念，需要采购材料，并且考虑交货时间也很重要。此外，这个过程很耗时，因为药物需要足够的时间完成所有临床试验，然后才能投入市场使用。
此外，任何必须重新验证的更改都会影响时间。生物传感器检测格式和其他补充技术的不断进步需要有效的投资才能成功运营并制定项目风险管理计划。建立研发机构进行研究需要高昂的成本，从而导致药物价格昂贵。因此，这一因素是中东和非洲脂质市场的主要制约因素。
- 脂质纳米颗粒生产面临的不同制造挑战
脂质纳米颗粒对制药行业产生了重大影响。脂质纳米颗粒 (LNP) 的核心是保护核酸的递送载体。作为近期 mRNA 疫苗的重要组成部分，它们被注射并运送到细胞中的预定位置。尽管脂质纳米颗粒作为递送系统具有许多优势，但制药行业必须应对重大的制造挑战。
这些挑战包括：
- 精确控制粒度/尺寸分布
- 灭菌问题
- 流程可重复性和可扩展性
- 监管要求（如 cGMP 法规）
COVID-19 对脂质市场的影响
COVID-19 对市场产生了积极影响。由于对 COVID-19 疫苗的需求很大，而且积极的一点是脂质主要用于疫苗生产。因此 COVID-19 对脂质市场产生了积极影响。
最新动态
- 2022 年 11 月，BioNTech SE 宣布其新加坡子公司 BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. 已与 Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. 达成协议，收购其一家经 GMP 认证的制造工厂。此次收购是 BioNTech 扩张战略的一部分，旨在加强其在亚洲的中东和非洲业务。
- 2021 年 9 月，美国配料供应商 ABITEC Corporation 与 DKSH 签署了一项修订协议，将其特种脂质分销到欧洲各地的新市场和地区。这有助于该公司在各个地区拓展业务。
中东和非洲脂质市场范围
中东和非洲脂质市场细分为类型、脂质系统、交付系统、来源、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
类型
- 天然脂质
- 合成脂质
根据类型，中东和非洲脂质市场分为天然脂质和合成脂质。
脂质系统
- 生物活性脂质
- 可聚合脂质
- 荧光脂质
- 细菌脂质
- 中性脂质
- 头基修饰脂质
- 其他的
根据脂质系统，中东和非洲脂质市场分为中性脂质、细菌脂质、荧光脂质、生物活性脂质、可聚合脂质、头部改性脂质和其他。
交付系统
- 脂质体
- 固体脂质纳米颗粒
- 纳米结构脂质载体
- 转运体
- 囊泡
- 其他的
根据输送系统，中东和非洲脂质市场细分为脂质体、固体脂质纳米颗粒、纳米结构脂质载体、囊泡、转移体和其他。
来源
- 纯化脂肪酸
- 精制油
- 蛋黄
- 大豆
- 非转基因大豆
- 其他的
根据来源，中东和非洲脂质市场分为蛋黄、大豆、非转基因大豆、纯化油、纯化脂肪酸和其他。
最终用户
- 制药行业
- 生物科技产业
- 化妆品行业
- 学术及研究机构
- 其他的
根据最终用户，中东和非洲脂质市场分为制药行业、生物技术行业、学术和研究机构、化妆品行业和其他行业。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，中东和非洲脂质市场分为直接招标、零售和其他。
脂质市场区域分析/见解
对脂质市场进行分析，并按国家、类型、脂质系统、输送系统、来源、最终用户和分销渠道提供市场规模见解和趋势。
脂质市场覆盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。
由于对药品的需求量大，慢性病发病率上升，预计南非将出现增长，而不同行业对脂质的需求不断增加，预计将在预测期内推动区域市场的发展。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和脂质市场份额分析
脂质市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对脂质市场的关注有关。
脂质市场的一些主要参与者包括 Alnylam Pharmaceutical, Inc.、Croda International Plc.、Moderna Inc.、BioNTech SE.、Pfizer Inc.、Evonik Industries AG、Lipoid GmbH、Matreya LLC、VAV Life Sciences Pvt Ltd.、Curia Middle East and Africa Inc.、Cargill, Incorporated、Gattefossé、CD Bioparticles、Merck KGaA、NOF EUROPE GmbH、ABITEC、Cayman Chemical、CordenPharma International、CHEMI SpA、DSM、BASF SE、Tokyo Chemical Industry Co., Ltd.、ADMSIO、Stepan Company 和 Kerry 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LIPIDS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 MERGER AND ACQUISITION, MIDDLE EAST & AFRICA LIPIDS MARKET
4.4 PATENT ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
4.7 KEY PRICING STRATEGIES
4.8 KEY PATIENT ENROLLMENT STRATEGIES
4.9 PRICE ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET
4.1 MIDDLE EAST & AFRICA LIPIDS MARKET, CLINICAL TRIALS
4.11 MIDDLE EAST & AFRICA LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE
4.12 MIDDLE EAST & AFRICA LIPIDS MARKET, PIPELINE ANALYSIS
4.13 PHASE I CANDIDATES
4.14 PHASE I/II CANDIDATES
4.15 PHASE II CANDIDATES
4.16 PHASE III CANDIDATES
5 MIDDLE EAST & AFRICA LIPIDS MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN THE U.S.:
5.2 REGULATION IN EUROPE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY
6.1.3 INCREASE IN DRUG DEVELOPMENT
6.2 RESTRAINTS
6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS
6.2.2 STRICT GOVERNMENT REGULATIONS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION
6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES
7 MIDDLE EAST & AFRICA LIPIDS MARKET, BY TYPE
7.1 OVERVIEW
7.2 NATURAL LIPID
7.2.1 UNSATURATED PHOSPHOLIPID
7.2.2 HYDROGENATED PHOSPHOLIPID
7.2.3 SPHINGOMYELIN
7.2.4 GLYCEROLPHOSPHOCHOLINE
7.3 SYNTHETIC LIPID
7.3.1 PEGYLATED PHOSPHOLIPIDS
7.3.2 PHOSPHATIDYLSERINE
7.3.3 PHOSPHATIDYGLYCEROLS
7.3.4 PHOSPHATIDYLETHANOLAMINE
7.3.5 PHOSPHATIDYLCHOLINE
7.3.6 PHOSPHATIDIC ACIDS
8 MIDDLE EAST & AFRICA LIPIDS MARKET, BY LIPID SYSTEMS
8.1 OVERVIEW
8.2 BIOACTIVE LIPIDS
8.2.1 PLANT LIPIDS
8.2.2 LIPID ACTIVATORS
8.2.3 LIPID INHIBITORS
8.2.4 AGONISTS
8.2.5 BIOACTIVE CERAMIDES
8.2.6 ACYL CARNITINE LIPIDS
8.2.7 ENDOCANNABINOIDS
8.2.8 LIPO-NUCLEOTIDES
8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL
8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP)
8.3 POLYMERIZABLE LIPIDS
8.3.1 FUNCTIONAL PEG LIPIDS
8.3.2 MPEG STEROLS
8.3.3 MPEG CERAMIDES
8.3.4 MPEG PHOSPHOLIPIDS
8.3.5 MPEG GLYCERIDES
8.4 FLUORESCENT LIPIDS
8.4.1 FLUORESCENT SPHINGOLIPIDS
8.4.2 FLUORESCENT GLYCEROLIPIDS
8.4.3 FLUORESCENT PEG LIPIDS
8.4.4 FLUORESCENT PHOSPHOLIPIDS
8.4.5 FLUORESCENT STEROLS
8.4.6 OTHERS
8.5 BACTERIAL LIPIDS
8.5.1 MYCOLIC LIPIDS
8.5.2 N-ACYLHOMOSERINE LIPIDS
8.5.3 BRANCHED LIPIDS
8.5.4 CYCLOPROPYL LIPIDS
8.6 NEUTRAL LIPIDS
8.6.1 PRENOLS
8.6.2 VERY LONG CHAIN FATTY ACIDS
8.6.3 GLYCERIDES
8.6.4 EICSANOIDS
8.6.5 OXYGENATED FATTY ACIDS
8.6.6 GLYCOSYLATED DIACYL GLYCEROLS
8.6.7 PROSTAGLANDINS
8.7 HEADGROUP MODIFIED LIPIDS
8.7.1 FUNCTIONAL LIPIDS
8.7.2 ANTIGENIC LIPIDS
8.7.3 GLYCOSYLATED LIPIDS
8.7.4 CHELATORS
8.7.5 ADHESIVE LIPIDS
8.7.6 SNAP-TAG REACTING LIPIDS
8.7.7 ALKYL PHOSPHATES
8.8 OTHERS
9 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS
9.1 OVERVIEW
9.2 LIPOSOMES
9.2.1 LIPOSOMES FOR DNA/RNA
9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.2 REACTIVE LIPOSOMES
9.2.2.1 SUCCINYL LIPOSOMES
9.2.2.2 DBCO LIPOSOMES
9.2.2.3 BIOTINYLATED LIPOSOMES
9.2.2.4 CARBOXYLIC ACID LIPOSOMES
9.2.2.5 AMINE LIPOSOMES
9.2.2.6 CYANUR LIPOSOMES
9.2.2.7 AZIDE LIPOSOMES
9.2.2.8 FOLATE LIPOSOMES
9.2.2.9 DODECANYL LIPOSOMES
9.2.2.10 NI REACTIVE LIPOSOMES
9.2.2.11 PDP LIPOSOMES
9.2.2.12 GLUTARYL LIPOSOMES
9.2.2.13 OTHERS
9.2.3 DRUG LOADED LIPOSOMES
9.2.4 PLAIN LIPOSOMES
9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES
9.2.4.2 DOTAP LIPOSOMES
9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES
9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES
9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES
9.2.4.6 OTHERS
9.3 SOLID LIPID NANOPARTICLES
9.4 NANOSTRUCTURES LIPID CARRIER
9.5 TRANSFEROSOMES
9.6 NIOSOMES
9.7 OTHERS
10 MIDDLE EAST & AFRICA LIPIDS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 PURIFIED FATTY ACIDS
10.3 PURIFIED OILS
10.4 EGG YOLK
10.5 SOYABEAN
10.6 NON-GMO SOYABEAN
10.7 OTHERS
11 MIDDLE EAST & AFRICA LIPIDS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL INDUSTRIES
11.3 BIOTECHNOLOGY INDUSTRIES
11.4 COSMETIC INDUSTRIES
11.5 ACADEMIC AND RESEARCH INSTITUTES
11.6 OTHERS
12 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST & AFRICA LIPIDS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E.
13.1.4 EGYPT
13.1.5 ISRAEL
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BIONTECH SE.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 MODERNA, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PFIZER INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 CARGILL, INCORPORATED.
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KERRY.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 ABITEC
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ADMSIO
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ALNYLAM PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BASF SE
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CAYMAN CHEMICAL
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 CD BIOPARTCLES.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CHEMI S.P.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 CORDENPHARMA INTERNATIONAL
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 CRODA INTERNATIONAL PLC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 CURIA MIDDLE EAST & AFRICA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 DSM
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 EVONIK INDUSTRIES AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 GATTEFOSSÉ
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 LIPOID GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 MATREYA, LLC
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 MERCK KGAA
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENTS
16.22 NOF EUROPE GMBH
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 STEPAN COMPANY
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD.
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 VAV LIFE SCIENCES PVT LTD
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASP FOR MAJOR DRUGS IN LIPIDS MARKET (PRICE IN USD)
TABLE 2 LIPID BASED NANO PARTICLE FOR COVID-19 VACCINES
TABLE 3 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 4 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 5 LIPOSOMAL FORMULATIONS
TABLE 6 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 7 LIPOSOMAL FORMULATION
TABLE 8 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 9 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 10 LIPOSOME FORMULATIONS
TABLE 11 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 12 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 13 LIPOSOMAL FORMULATION
TABLE 14 MIDDLE EAST & AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA NATURAL LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA SYNTHETIC LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA LIPOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA SOLID LIPID NANOPARTICLES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA NANOSTRUCTURES LIPID CARRIER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA TRANSFEROSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA NIOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA PURIFIED FATTY ACIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA PURIFIED OILS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA EGG YOLK IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA NON-GMO SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA PHARMACEUTICAL INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA BIOTECHNOLOGY INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA COSMETIC INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA DIRECT TENDER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA RETAIL SALES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 89 SOUTH AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 93 SOUTH AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 96 SOUTH AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 SOUTH AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 106 SAUDI ARABIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 107 SAUDI ARABIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 108 SAUDI ARABIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 109 SAUDI ARABIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 110 SAUDI ARABIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 111 SAUDI ARABIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 SAUDI ARABIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 U.A.E. LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.A.E. NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 U.A.E. SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E. LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 120 U.A.E. NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 121 U.A.E. BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 122 U.A.E. FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 123 U.A.E. BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 124 U.A.E. POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 125 U.A.E. HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 126 U.A.E. LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 127 U.A.E. LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 128 U.A.E. LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 129 U.A.E. REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 130 U.A.E. PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 131 U.A.E. LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 132 U.A.E. LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 U.A.E. LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 EGYPT LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 136 EGYPT SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 137 EGYPT LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 138 EGYPT NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 139 EGYPT BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 140 EGYPT FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 141 EGYPT BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 142 EGYPT POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 143 EGYPT HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 144 EGYPT LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 145 EGYPT LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 146 EGYPT LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 147 EGYPT REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 148 EGYPT PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 149 EGYPT LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 150 EGYPT LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 151 EGYPT LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 152 ISRAEL LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 153 ISRAEL NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 160 ISRAEL POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 161 ISRAEL HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 162 ISRAEL LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 163 ISRAEL LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 164 ISRAEL LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 165 ISRAEL REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 166 ISRAEL PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 167 ISRAEL LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 168 ISRAEL LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 ISRAEL LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 REST OF MIDDLE EAST AND AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LIPIDS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LIPIDS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LIPIDS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LIPIDS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LIPIDS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA LIPIDS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LIPIDS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LIPIDS MARKET
FIGURE 14 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022
FIGURE 19 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022
FIGURE 23 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2022
FIGURE 27 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2022
FIGURE 31 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA LIPIDS MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY TYPE (2023 & 2030)
FIGURE 43 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
